These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21562066)

  • 1. The predictive value of inflammatory activity and markers of the adipo-insular axis on restenosis in patients with type 2 diabetes.
    Hage C; Grip L; Malmberg K; Rydén L; Wallander M; Saleh N
    Diab Vasc Dis Res; 2011 Apr; 8(2):143-9. PubMed ID: 21562066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study.
    Hage C; Norhammar A; Grip L; Malmberg K; Sarkar N; Svane B; Rydén L
    Diab Vasc Dis Res; 2009 Apr; 6(2):71-9. PubMed ID: 20368196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.
    Fang CC; Ng Jao YT; Yi-Chen ; Yu CL; Chen CL; Wang SP
    Angiology; 2007; 58(5):523-34. PubMed ID: 18024934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention.
    McNair ED; Wells CR; Mabood Qureshi A; Basran R; Pearce C; Orvold J; Devilliers J; Prasad K
    Clin Cardiol; 2010 Nov; 33(11):678-85. PubMed ID: 21089112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine.
    Ari H; Ari S; Erdoğan E; Tiryakioğlu O; Ustündağ Y; Huysal K; Koca V; Bozat T
    Heart Vessels; 2010 Jan; 25(1):19-26. PubMed ID: 20091394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Joint effects of N-terminal pro-B-type-natriuretic peptide and C-reactive protein vs angiographic severity in predicting major adverse cardiovascular events and clinical restenosis after coronary angioplasty in patients with stable coronary artery disease.
    Dai DF; Hwang JJ; Lin JL; Lin JW; Hsu CN; Lin CM; Chiang FT; Lai LP; Hsu KL; Tseng CD; Tseng YZ
    Circ J; 2008 Aug; 72(8):1316-23. PubMed ID: 18654020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambulatory blood pressure variability is associated with restenosis after percutaneous coronary intervention in normotensive patients.
    Cay S; Cagirci G; Demir AD; Balbay Y; Erbay AR; Aydogdu S; Maden O
    Atherosclerosis; 2011 Dec; 219(2):951-7. PubMed ID: 22005197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
    Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
    Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-type natriuretic peptide as a marker of asymptomatic re-stenosis after coronary implantation of a paclitaxel-eluting stent.
    Lo Mauro R; Arcoleo F; Lo Giudice A; Picone A; Schirosa M; Raspanti G; Cillari E; Enia F
    J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1020-3. PubMed ID: 18163013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced inflammatory response to coronary stenting marks the development of clinically relevant restenosis.
    Caixeta AM; Brito FS; Costa MA; Serrano CV; Petriz JL; Da Luz PL
    Catheter Cardiovasc Interv; 2007 Mar; 69(4):500-7. PubMed ID: 17285569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement.
    Lazzeri C; Chiostri M; Sori A; Valente S; Gensini GF
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):7-13. PubMed ID: 19829142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
    Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
    Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the cut-off plasma adiponectin level associated with a lower risk of restenosis in patients with stable angina.
    Mito T; Miura S; Iwata A; Morii J; Sugihara M; Ike A; Mori K; Kawamura A; Nishikawa H; Zhang B; Saku K
    Coron Artery Dis; 2011 Nov; 22(7):451-7. PubMed ID: 21811155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study.
    Sasso FC; Pafundi PC; Marfella R; Calabrò P; Piscione F; Furbatto F; Esposito G; Galiero R; Gragnano F; Rinaldi L; Salvatore T; D'Amico M; Adinolfi LE; Sardu C
    Cardiovasc Diabetol; 2019 Mar; 18(1):24. PubMed ID: 30832662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of interleukin-6 and transforming growth factor-beta1 in predicting restenosis within stented infarct-related artery.
    Szkodzinski J; Blazelonis A; Wilczek K; Hudzik B; Romanowski W; Gasior M; Wojnar R; Lekston A; Polonski L; Zubelewicz-Szkodzinska B
    Int J Immunopathol Pharmacol; 2009; 22(2):493-500. PubMed ID: 19505401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.
    Patel D; Walitt B; Lindsay J; Wilensky RL
    JACC Cardiovasc Interv; 2011 Mar; 4(3):353-60. PubMed ID: 21435616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome.
    Sukhija R; Fahdi I; Garza L; Fink L; Scott M; Aude W; Pacheco R; Bursac Z; Grant A; Mehta JL
    Am J Cardiol; 2007 Apr; 99(7):879-84. PubMed ID: 17398176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes after bare-metal stenting in diabetic patients with lesions carrying a low risk of restenosis.
    Woudstra P; Damman P; Beijk MA; Grundeken MJ; Harskamp RE; Koch KT; Henriques JP; Baan J; Vis MM; Piek JJ; Tijssen JG; de Winter RJ
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):26-33. PubMed ID: 22511590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis.
    Saleh N; Tornvall P
    Atherosclerosis; 2007 Dec; 195(2):374-8. PubMed ID: 17126343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma B-type natriuretic peptide level can predict myocardial tissue perfusion in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
    Seo SM; Kim S; Chang K; Min J; Kim TH; Koh YS; Park HJ; Shin WS; Lee JM; Kim PJ; Chung WS; Seung KB
    Coron Artery Dis; 2011; 22(6):405-10. PubMed ID: 21701385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.